These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31082687)

  • 1. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
    Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
    Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
    Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
    Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
    [No Abstract]   [Full Text] [Related]  

  • 3. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
    Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
    J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
    Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
    J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
    J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
    Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
    JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
    Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
    Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
    Bocquet-Tremoureux S; Scharbarg E; Nguyen JM; Varey E; Quereux G; Saint-Jean M; Peuvrel L; Khammari A; Dreno B
    Eur J Dermatol; 2019 Jun; 29(3):315-321. PubMed ID: 31389790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 79-year Old Man on Nivolumab with Itchy Erythematous Patches.
    Copur MS; Corey S
    Oncology (Williston Park); 2020 Feb; 34(2):53-54. PubMed ID: 32645195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M; Uhara H; Koga H; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.